$5.980
+0.091 (+1.53%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
CTKB 相似圖表分析預測
Alphio's CTKB stock price prediction model matches the current Cytek Biosciences Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $6.15 (+0.20%). The 1-week path is $6.07 (-1.15%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Cytek Biosciences Inc 股票嗎？
Cytek Biosciences Inc is a good buy right now due to its current price of $5.59, which is above the analyst target price of $5.50, and a strong RSI of 64.25 indicating bullish momentum. The company has shown a year-to-date change of +13.62%, reflecting positive market sentiment. However, the main risk is the forward P/E ratio of 370.37, indicating potential overvaluation concerns.
CTKB 股價於 Tuesday 收在 $5.98，此前上漲 +1.53%
Cytek Biosciences Inc (CTKB) last closed at $6.1399999, gaining +2.68%. These facts feed the 1-day and 1-week CTKB price prediction above.
預測驅動因素
Cytek Biosciences Inc（CTKB）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bullish
相似圖表形態
近期走勢與 CTKB 最接近的股票，依相似度排序。
CTKB 季節性分析
Historically the probability of a positive October return for CTKB is 31.34%. January offers the highest probability of a positive month at 44.26%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
CTKB 十年價格預測
| 月份 | 最低價 | 平均價 | 最高價 | 潛在報酬率 |
|---|---|---|---|---|
| Oct 2026 | $2.03 | $2.36 | $2.43 | -61.60% |
| Nov 2026 | $1.85 | $2.18 | $2.39 | -64.53% |
| Dec 2026 | $2.40 | $2.89 | $3.14 | -52.95% |
2026 年，Cytek Biosciences Inc（CTKB）預計區間為 $1.85 至 $3.14。
Cytek Biosciences Inc 2026 年月度預測
2026 年 Oct，Cytek Biosciences Inc 預計均價 $2.36，最低 $2.03，最高 $2.43。
2026 年 Nov，Cytek Biosciences Inc 預計均價 $2.18，最低 $1.85，最高 $2.39。
2026 年 Dec，Cytek Biosciences Inc 預計均價 $2.89，最低 $2.40，最高 $3.14。
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。